Achaogen Raises $56M In Series C Round To Advance Next-Generation Antibiotic Programs
This article was originally published in The Pink Sheet Daily
Executive Summary
Achaogen turns to VC backers to advance its lead compound into Phase II trials for complicated urinary tract infections.